A New Amino Acid Supplement for Cancer Patients
Invented by Recovery Plus®️ Nutrition Science Department
R+ Amino acid limited powder featured on Cell Metabolism cover.
"Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation."
Cell Metabolism, Volume 36, Issue 12 | IF: 27.7 | December 3, 2024
Recovery Plus®️ Amino Acid Limited Powder is a clinically proven dietary formula designed to support cancer patients. By restricting specific amino acids like serine and glycine, this formulation enhances anti-tumor immunity and improves response to PD-1/PD-L1 immunotherapy.
For The First Time
It can inhibit tumor growth, enhance antitumor immunity, and have a lasting impact on tumors.
(Marked by )
It can combine with anti-PD-1/PD-L1 immunotherapy to make cancer sensitive to PD-1 treatment.
(Marked by )
Verified through Clinical Trials
Comparison before and after the treatment of an esophageal cancer patient using R+ Amino acid limited powder and immunotherapy.
Proven feasible and safe in clinical trials, with no impacts on the body mass index (BMI) and quality of life of patients.
Overall response rate (ORR) was 25%.
Clinical benefit rate (CBR) was 90%.
Frequently Asked Questions
What is Recovery Plus®️ Amino Acid Limited Powder?
A supplement designed to restrict amino acids like serine/glycine to support cancer treatment.
Is this product backed by scientific research?
Yes, it was featured on the cover of Cell Metabolism, Dec 3, 2024.
Who can use this product?
It is intended for patients undergoing cancer therapy, especially those receiving immunotherapy.